Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)...

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute U.S. Patent and Trademark Office extends protection of Clearmind’s  proprietary MEAI and expands its potential market  Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) --...

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100 The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,CSE:...

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink:...